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Abstract
Background: Array comparative genomic hybridization (CGH) is currently the most powerful method for detecting
chromosomal alterations in pre and postnatal clinical cases. In this study, we developed a BAC based array CGH
analysis platform for detecting whole genome DNA copy number changes including specific micro deletion and
duplication chromosomal disorders. Additionally, we report our experience with the clinical implementation of our
array CGH analysis platform. Array CGH was performed on 5080 pre and postnatal clinical samples from patients
referred with a variety of clinical phenotypes.
Results: A total of 4073 prenatal cases (4033 amniotic fluid and 40 chorionic villi specimens) and 1007 postnatal
cases (407 peripheral blood and 600 cord blood) were studied with complete concordance between array CGH,
karyotype and fluorescence in situ hybridization results. Among 75 positive prenatal cases with DNA copy number
variations, 60 had an aneuploidy, seven had a deletion, and eight had a duplication. Among 39 positive postnatal
cases samples, five had an aneuploidy, 23 had a deletion, and 11 had a duplication.
Conclusions: This study demonstrates the utility of using our newly developed whole-genome array CGH as first-
tier test in 5080 pre and postnatal cases. Array CGH has increased the ability to detect segmental deletion and
duplication in patients with variable clinical features and is becoming a more powerful tool in pre and postnatal
diagnostics.
Background
Array comparative genomic hybridization (CGH) was
developed as a genome wide screening strategy for detect-
ing DNA copy number changes mainly in chromosomal
disorders and cancer research [1-4]. Chromosomal
abnormalities are a major cause of congenital and develop-
mental abnormalities in human genetic diseases including
dysmorphic features, mental retardation and developmen-
tal delay, and multiple congenital anomalies. Karyotype
analysis has been the gold standard for pre and postnatal
diagnosis. Using traditional cytogenetic techniques, chro-
mosomal imbalances such as aneuploidies and segmental
abnormalities must be larger than about 3~5 Mb to be
detected by GTG banding. In the past two decades,
various traditional banding techniques have been com-
bined with molecular cytogenetic technologies to improve
the resolution at which genomic changes can be detected.
Array CGH technology has higher resolution and excellent
throughput when compared to conventional and molecu-
lar cytogenetics. In array CGH, genomic DNA from the
patient and reference are labeled with different fluorescent
dyes and co-hybridized to an array matrix containing
cloned DNA. The content of an array may include specific
targeted regions of the genome or the entire genome
arrayed on a single glass slide. Similar to conventional
CGH, genome imbalances are quantified by analyzing the
ratio of the two fluorescent hybridizing signals. The reso-
lution of array CGH is determined by the size and number
of the clones placed on the array to interrogate genome
copy number changes. Whole genome or targeted array
CGH is a powerful tool to accurately detect subtelomeric
rearrangements. Array CGH has higher resolution and
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any medium, provided the original work is properly cited.powerful clinical utility when compared with conventional
and other molecular cytogenetic technologies. Array CGH
has successfully detected DNA copy number changes, and
several groups have studied the clinical application of this
technology in both prenatal and postnatal samples [5-9].
Recently, The International Standard Cytogenomic Array
(ISCA) Consortium reported consensus statement on the
use of chromosomal microarray as a first-tier diagnostic
test in the evaluation of individuals with developmental
delays and/or congenital anomalies [10,11]. Our group
successfully developed and validated a bacterial artificial
chromosome (BAC) based array CGH analysis platform
including analysis software [12]. This BAC array CGH
analysis platform is based on 1440 fluorescence in situ
hybridization (FISH) verified BAC clones that were
selected among 100,000 BAC clones constructed by the
Asian Genome Project [13] and validated by end-sequen-
cing and FISH. This array CGH contains whole genomic
regions including 356 major cell-growth related genes and
over 40 known DNA copy number change disorders.
In this study, we applied our newly developed array
CGH platform to 5080 clinical pre and postnatal cases
and identified 114 abnormal cases with 75 prenatal and
39 postnatal cases. Our results support previous reports
of the utility of array CGH for detecting chromosomal
DNA copy number variations in prenatal and postnatal
clinical cases.
Materials and methods
1) Clinical samples
We analyzed the results obtained from 5080 clinical
cases referred to MG MED laboratories for array CGH
analysis between April 2007 and December 2009. We
studied 4073 prenatal cases (4033 Amniotic Fluid [AF]
and 40 Chorionic Villi [CV]) and 1007 postnatal cases
(407 Peripheral Blood [PB] and 600 Cord Blood [CB]).
The indications for the 4073 prenatal cases were family
history, advanced maternal age, fetal ultrasound anoma-
lies, elevated serum alpha fetoprotein, and parental anxi-
ety. The indications for the 407 postnatal cases were
mainly developmental delay, mental retardation, and
multiple congenital abnormalities. The 600 postnatal
cord blood samples were collected from the cord blood
bank for detecting genomic imbalances, which were sub-
mitted by obstetricians, pediatricians, and geneticists. All
samples were well prepared for experiments using pre-
viously described methods [12]. Appropriate ethical
approval was obtained, and informed consent for the
genetic testing was obtained from all patients.
2) Development of the array CGH analysis platform
We developed an BAC based array CGH analysis plat-
form for detecting genomic imbalances in human
genetic diseases [12]. Our array CGH chip consists of
1440 non-overlapping BAC clones (MACArray Karyo
1440 BAC-chip, Macrogen, Seoul, South Korea). A total
of 1440 clone locations are shown on this website
(http://www.macrogen.co.kr/eng/biochip/genelist_over-
view.html), which were selected among 100,000 BAC
clones constructed by the Asian Genome Project [13,14]
and carefully mapped, end-sequenced, and fluorescently
labeled by FISH. All clones were two-end sequenced
using an ABI PRISM 3700 DNA Analyzer (Applied Bio-
systems, Foster City, CA), and their sequences were
Blast analyzed and mapped according to their positions
as described in the University of California, Santa Cruz
(UCSC) human genome database (http://www.genome.
ucsc.edu). Confirmation of the locus specificity of the
chosen clones was performed by removing multiple loci-
binding clones by individual examination using standard
FISH procedures as described previously.
3) Array CGH and data analysis
DNA was extracted from AF, CB, PB and CV using the
PureGene kit (Gentra Systems, Minneapolis, MN). After
extracting the DNA, we labeled 50~500 ng of both test
and reference DNA with Cy 3- and Cy 5-dCTP (Perkin
Elmer) by a random priming method using Exo-Klenow
Fragment (Invitrogen, Carlsbad, CA) for 16 hr. labeled
according to the manufacturer’s recommendations.
Reported here are pre and postnatal cases tested using
the BAC chip. The array CGH chip data were analyzed
using the chromofluor image analysis system (Array
Analysis; Macrogen, South Korea). The slides contained
1440 human BAC clones including specific loci of more
than 40 chromosomal disorders and 356 cell growth
related genes from BAC libraries at a resolution average
of 2.3 Mb for the entire genome. The human DNA
source for making the BAC library was human sperm
derived from a Korean man. Each BAC clone was repre-
sented on an array as triplicate spots, and each array
was scanned using a GenePix4000B scanner (Axon
Instruments, Foster City, CA, USA) and analyzed with
array software (MAC VIEWER, Macrogen, South
Korea). Green (test) to red (reference) (G/R) ratios were
automatically determined for each sample, and the nor-
malized G/R ratio represented the relative average num-
ber of copies of the sequence for those spots that were
selected as controls. Spots with G/R ratios more than
the mean plus 2.5 standard deviations (1.25) were con-
sidered amplifications or gains of the indicated copy
number; less than the mean minus 2.5 deviations (-0.75)
were considered losses of the copy number.
4) Karyotype and FISH with region-specific probes
analyses
The chromosome analysis was performed according to
standard methods using cultured cells from amniotic
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patient and available parents. Metaphase preparations
were analyzed by G-banding techniques. FISH studies
on interphase or metaphase spreads with specific probes
were performed following the manufacturer’sp r o t o c o l s
(Macrogen). FISH was performed with specific BAC
clones to confirm the array CGH analysis. FISH was
performed mainly with two color probes; the specific
BAC probes labeled with Cy3 (red) and the control
probe (green) with FITC. The specific BAC probes were
constructed using BAC clone DNA (NCBI build35).
FISH was performed on metaphase chromosomes cul-
tured from amniotic fluid and peripheral blood lympho-
cytes from each patients and available parents. Image
acquisition of metaphase cells and subsequent karyotyp-
ing were performed using the CytoVision system
(Applied Imaging, Santa Clara, CA, USA). A karyotype
was characterized according to the conventions of the
International System for Human Cytogenetic Nomencla-
ture (ISCN, 2009).
Results
Array CGH is currently the most powerful method for
simultaneously detecting genomic alterations. We per-
formed whole genome array CGH using CGH array
slides containing 1440 clones including about 40 chro-
mosomal disorders specificl o c ia n d3 5 6c e l lg r o w t h
related genes from BAC libraries in 5080 pre and post-
natal cases (Table 1). We simultaneously performed
FISH and a G-banding analysis to confirm abnormal
array CGH results. In all prenatal cases, we performed
array CGH analysis and concurrent karyotype analysis.
We detailed genotype-phenotype correlations as far as
possible in postnatal cases.
Of 4073 prenatal cases (4033 AF and 40 CV speci-
mens), we identified 75 positive cases (75/4073 = 1.8%)
with DNA copy number variations; 60 had an aneu-
ploidy, seven had a deletion, and eight had a duplication
(Table 2). Thirty-six cases had an autosomal aneuploidy,
and 24 cases had a sex chromosome aneuploidy. The
detection rate of overall chromosomal rearrangements
including balanced translocations and inversions by kar-
yotype analysis was 3.8% (155/4073). In prenatal cases,
we identified deletion/micro deletion breakpoints (2q13,
7q11.23, 17p11.2, Xp22.31, and Xq24qter) and duplica-
tion/micro duplication chromosomes (1q42q44,
15q11.2q12, 21q11.2, Xp22.31, Xp21.2, and Xq27.2qter).
A heterozygous micro deletion at 2q13, which includes
the Joubert syndrome (2q13 homozygous deletion) criti-
cal region, was observed in two cases. The array CGH
results were normal in two marker chromosome cases.
The marker chromosomes seemed to consist of mainly
heterochromatin or this may have been due to the lim-
ited array CGH coverage.
A total of 1007 postnatal cases (407 PB and 600 CB)
were studied with complete concordance between array
CGH, karyotype and FISH results. Among the postnatal
cases with 39 positive cases, five had an aneuploidy, 23 had
a deletion, and 11 had a duplication (Table 3). We identi-
fied breakpoints on 17 types of deletion/micro deletion and
seven types of duplication/micro duplication chromosomes.
The most common indications for referral in the 407 PB
cases were developmental delay, mental retardation, conge-
nital abnormalities, and dysmorphic features. We identified
34 deletion/duplication cases (34/407 = 8.3%) in 407 PB
cases with clinical indications. In 600 CB cases for screen-
ing genomic imbalances from the cord blood bank, we
found four deletion (15q11.2, 22q11.2, and Xp11.2petr)
cases and one duplication (2q13) case (5/600 = 0.83%).
Thirty-four cases had segmental gains or losses associated
with chromosomal deletion (micro deletion) or duplication
(micro duplication), including Wolf-Hirschhorn syndrome
(WHS)(4p16.3), Cri-du-chat syndrome (5p15.3), Soto’ss y n -
drome (5q35.3), William’s syndrome (7q11.23), Digeorge
syndrome 2 (10p14), Prader Willi/Angelman syndrome
(15q11.2), Digeorge syndrome (22q11.2), steroid sulfatase
deficiency (Xp22.31), Cat eye syndrome (22q11.2), and
Emanuel syndrome (22q11, 11q23). We performed array
CGH, and the molecular cytogenetic results are shown in
Figure 1 (examples of prenatal deletion/duplication cases)
and 2 (examples of postnatal deletion/duplication cases).
We also found clinical features in the postnatal cases. For
Table 1 Summary of array CGH analysis in 5080 cases
Cases with abnormal array CGH analysis
a Total (N) Detection rate (%)
Aneuploidy (N) Deletion (N) Duplication (N)
Prenatal cases
b (N = 4073) 60 7 8 75 1.8
Postnatal cases (N = 1007) PB with clinical indications
c (N = 407) 5 19 10 34 8.3
CB (N = 600) 0 4 1 5 0.83
Total 5080 65 30 19 114 2.24
PB, Peripheral Blood; CB, Cord Blood for banking in general population
aKaryotype and FISH analyses performed with array CGH anaysis. FISH analyses were performed using specific bacterial artificial chromosome (BAC) clones.
bAF, Amniotic Fluid (N = 4033); CV, Chorionic Villi (N = 40)
cClinical indications; developmental delay, mental retardation, dysmorphic feature, multiple congenital anomalies, etc.
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was a 1.1-year-old male with a birth weight of 4.1 kg. He
had typical facial features including macrocephaly, sparse-
ness of frontotemporal hair, high bossed forehead, a long
narrow face and prominent narrow jaw, developmental
delay, overgrowth, abnormally large hands, and a café au
lait spot. We identified not only simple deletion and dupli-
cation but also multiple copy number abnormalities includ-
ing various chromosomal rearrangements (postnatal cases
4, 24, 27, and 30). Additionally, postnatal case 4 was identi-
fied with multiple rearrangements. Although we found a
2 q 1 4 q 2 1 . 1d e l e t i o nu s i n ga r r a yC G H ,w ew e r ea b l et oc h a r -
acterize accurate cytogenetic features as 46,XY, der(2)t(2;6)
(q21.1;q23)inv(2)(q14.1q37) and der(6)t(2;6)(q21.1;q23) by
concurrent karyotype analysis (data not shown). In case 30,
we identified two chromosomes involved as a small super-
numerary marker chromosome (sSMC) as 47,XX, +der(22)
t(11;22)(q23;q11) with mental retardation (Figure 2).
Discussion
Array CGH offers a high-resolution genome analysis in
a clinical setting [15]. Currently, many commercial and
academic laboratories have used BAC-based array, oligo-
nucleotide-based array or SNP-based arrays. Array reso-
lution is dependent on the number and types of probes
used and how they are designed on the genome. Current
commercial BAC arrays (targeted or whole genome)
generally have 600~5200 BAC clones (e.g. PerkinElmer).
Our whole-genome BAC array CGH platform is based
on 1440 fluorescence in situ hybridization (FISH)
Table 2 Summary of array CGH and cytogenetic analyses in 4073 prenatal cases
a
Case (number) Array CGH analysis
b Cytogenetic analyses
c
Aneuploidy
1 (1) Duplication of whole chr.13 Trisomy 13
2 (7) Duplication of whole chr.18 Trisomy 18
3 (28) Duplication of whole chr.21 Trisomy 21
4 (6) Duplication of whole chr.X 47,XXX
5 (7) Duplication of whole chr.X 47,XXY
6 (1) Duplication of whole chr.X Mos 47,XXY [18]/48,XXY,+17 [2]
7 (1) Copy number ratio of less than one copy loss at chr. 9 Mos 47,XXX [29]/48,XXX,+9 [11]
8 (1) Copy number ratio of less than one copy loss at chr.X Mos 47,XXY [32]/46,XY [8]
9 (1) Duplication of whole chr.X and 18 48,XXY,+18
10 (1) Duplication of long arm at Xq10qter/whole chr. 9 47,X,i(X)(q10),+9
11 (4) Deletion of whole chr.X 45,X
12 (1) Copy number ratio of less than one copy loss at chr.X Mos 45,X [22]/46,XX [8]
13 (1) Copy number ratio of less than one copy loss at chr.X Mos 45,X [10]/46,XX [20]
Deletion/Microdeletion
14 (2) Deletion of 0.5Mb at 2q13 46,XX,ish del(2)(q13q13)(NPHP1-)
15 (1) Deletion of 0.4Mb at 7q11.23 46,XY.ish del(7)(q11.23q11.23)(ELN-)
16 (2) Deletion of 0.4Mb at 17p11.2 46,XX.ish del(17)(p11.2p11.2)(D17S29-)
Deletion of 0.4Mb at 17p11.2 46,XY.ish del(17)(p11.2p11.2)(D17S29-)
17 (1) Deletion of 0.5Mb at Xp22.31 46,XY.ish del(X)(p22.31p22.31)(STS-)
18 (1) Deletion of 25Mb at Xq24qter 46,X,del(X)(q24qter)
Duplication/Microduplication
19 (1) Duplication of 10Mb at 1q42q44 46,XY.ish dup(1)(q42.1q44)(D1S491+)
20 (2) Duplication of 1.3Mb at 15q11.2q12 46,XX.ish dup(15)(q11.2q12)(SNRPN+)
21 (2) Duplication of 1.5Mb at 22q11.2 46,XY.ish dup(22)(q11.2q11.2)(COMT+)
22 (1) Duplication of 0.5Mb at Xp22.31 46,XX.ish dup(X)(p22.31p22.31)(KAL1+)
23 (1) Duplication of 0.5Mb at Xp21.2 46,XY.ish dup(X)(p21.2p21.2)(DMD+)
24 (1) Duplication of 5Mb at Xq27.2qter. 46,XY,ish dup(X)(q27.2qter)(DX904+)
Small supernumerary marker chromosome
25 (2) Normal 47,XX,+mar
Normal 47,XY,+mar
26 (80) Normal Others
d
aData compiled from array CGH and cytogenetic analyses in 4033 AF and 40 CV by the major indications for prenatal testing such as advanced maternal age,
fetal ultrasound anomalies, and elevated serum alpha fetoprotein .
blog2 mean green/red (G/R) ratios more than the mean + 2.5 SD (~ 0.25) were considered high
amplifications or gains of the indicated copy number, and less than the mean -2.5 SD (~ -2.5) were considered high losses of the copy number.
cperformed by
karyotype and FISH analyses. FISH analyses were performed using specific BAC clones.
dStructural balanced arrangements (inversion and translocation).
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BAC clones constructed by the Asian Genome Project
[13,14] and validated by end-sequencing and FISH.
Therefore, our abnormal array CGH results were able to
be confirmed by FISH, that BAC clones were available
to clinically relevant turnaround times.
In this study, we showed the utility of our whole-gen-
ome BAC-based array CGH platform in a large
Table 3 Summary of array CGH and cytogenetic analyses in 1007 postnatal cases
a
Case
(number)
Array CGH analysis
b Cytogenetic analyses
c Involved
Gene(s)
Clinical
indications
Aneuploidy
1 (3) Duplication of whole chr.21 Trisomy 21 DD,MR
2 Duplication of whole chr.X 47,XXY Klinefelter’s
syndrome
3 Duplication of whole chr.Y 47,XYY
Deletion/Microdeletion
4 Deletion of 15Mb at 2q14q21.1 46,XY, der(2)t(2;6)(q21.1;q23) Multiple DD,MR
inv(2)(q14.1q37), der(6)t(2;6)(q21.1;q23)
5 Deletion of 1Mb at 3q23q25 46,XY. ish del(3)(q23q25)(D3S1557-) ZIC1,4 DD,IA, CP
6 Deletion of 0.5Mb at 3q29 46,XY, ish del(3)(q29q29)(MF12-) PAK2,DLG1 DD
7 Deletion of 1Mb at 4p16.3 46,XX, del(4)(p16.3p16.3) WHSC1 WHS
8 Deletion of 0.8Mb at 4q35.1qter 46,XX.ish del(4)(q35.1qter)(D4S187-) Multiple DD
9(2) Deletion of 0.8Mb at 5p15.3 46,XY.ish del(5)(p15.3p15.3)(D5S2774-) Multiple DD,MR
10 Deletion of 0.5Mb at 5q35.2 46,XY.ish del(5)(q35.2q35.2)(NSD1-) NSD1 Sotos syndrome
11(2) Deletion of 0.4Mb at 7q11.23 46,XY.ish del(7)(q11.23q11.23)(ELN-) ELN Williams
syndrome
12 Deletion of 5Mb at 10p12.4p14 46,XY. ish del(10)(p12.4p14)(D10S585-) NEBL DGS2
13 Deletion of 0.5Mb at 12q14.3 46,XY.ish del(12)(q14.3q14.3)(D12S1448- ) LEMD3 DD
14 Deletion of 5Mb at 14q32.2qter 46,XX.ish del(14)(q32.2qter)(SHGC172944-) Multiple DD
15(2) Deletion of 0.5Mb at 15q11.2q11.2 46,XY.ish del(15)(q11.2q11.2)(SNRPN-) SNRPN PWS
16 Deletion of 0.4Mb at 17p11.2 46,XY.ish del(17)(p11.2p11.2)(PMP22-) PMP22
17 Deletion of 0.8Mb at 18p11.32 46,XX, ring(18)(p11.32q23) Multiple DD
18 (2) Deletion of 2.5Mb at 22q11.2 46,XY.ish del(22)(q11.2q11.2)(D22S75-) TBX1 DGS
19 (3) Deletion of 0.5Mb at Xp22.31 46,X.ish del(X)(p22.31p22.31)(STS-) STS ichthyosis, ADHD
20 Deletion of 1Mb at Yq11.2qter 46,X.ish del(Y)(q11.2qter)(CDY1-) CDY1 Azoospermia
Duplication/Microduplication
21 Duplication of 5Mb at 1q42.2qter 46,XY.ish dup(1)(q42.2qter)(D1S204+) Multiple
22 Duplication of 0.5Mb at 2q13 46,XX.ish dup(2)(q13q13)(NPHP1+) NPHP1
23 Duplication of 3Mb at 15q11.2q12 46,XX.ish dup(15)(q11.2q12)(SNRPN+) SNRPN DD,Autism,PD
24 Duplication of 0.9Mb at 21q22 & Deletion of
0.5Mb at 21q22
46,XY.ish del(21)(q22q22), dup(21)(q22q22)
(D21S1898+)
Multiple DD
25 (2) Duplication of 0.9Mb at 22q11.2 46,XY.ish dup(22)(q11.2q11.2)(D22S75+) TBX1 DD
26 Duplication of 0.9Mb at Yp11.2pter 46,X.ish i(Y)(p11.2pter)(DYS289+) SRY Azoospermia
27 Duplication of 3Mb at Yq11.2qter & 46,X.ish del(X)(p22.31p22.31), STS Short stature,
ADHD
Deletion of 0.5Mb at Xp22.31 dup(Y)(q11.2qter)(STS-,CDY1+) CDY1
Small supernumerary marker chromosome
28 Duplication of 3Mb at 18p11.2p11.3 47,XY,+der(18)(p11.2p11.32) Multiple DD
29 Duplication of 0.9Mb at 22q11.2qter 47,XY,+mar.ish i(22)(q11.2qter)(D22S43+) Multiple Cat eye
syndrome
30 Duplication of 2Mb at 22q11& 3Mb at 11q23 47,XX,+mar.ish +der(22)t(11;22)(q23;q11) (CES+,
D11S4145+)
Multiple Emanuel
syndrome
DD, developmental delay; MR, mental retardation; IA, imperforated anus; CP, cleft palate; WHS, Wolf-Hirschhorn syndrome; DGS, DiGeorge syndrome; PWS,
Prader-Willi syndrome; ADHD, Attention Deficit Hyperactivity Disorder; PD, Pigmentation disorder
aData compiled from 407 PB and 600 CB.
blog2 mean green/red ratios more than the mean +2.5 SD (~ 0.25) were considered high amplifications or gains of the indicated copy number, and less than the
mean -2.5 SD (~ -0.25) were considered high losses of the copy number.
cperformed by karyotype and FISH analyses. FISH analyses were performed using specific BAC clones.
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reported chromosomal abnormalities in ~1.3% of cases
[16]. Furthermore, previous postnatal studies have
shown that array CGH with cytogenetic analysis detects
clinically significant chromosome abnormalities in ~7%
of children referred for cytogenetic testing [16]. In this
study, the prenatal detection rate was 1.8% (75/4073)
and the postnatal detection rate with clinical indications
was 8.3% (34/407) using array CGH (Table 1). These
results are consistent with previous reports [17]. In
prenatal cases, we identified 11 types with DNA copy
number changes including five micro deletions and six
micro duplications. Because these micro deletion/dupli-
cation chromosomal abnormalities could not be
detected by conventional cytogenetic methods, array
CGH analysis was more useful. We also classified the
pathogenic variants. In case 14 (deletion at 2q13), we
identified a heterozygous deletion using FISH analysis.
Homozygous deletions of this locus (2q13 deletion) are
pathogenic variants related to Joubert syndrome [18].
Figure 1 Array CGH with FISH validation data for cases 17 (A, C) and 21 (B, D) (Table 2). (A) The array CGH results for the X chromosome.
Arrow indicates deletion of the steroid sulfatase deficiency critical region (Xp22.31) including the STS gene. (B) The array CGH results for
chromosome 22. Arrow indicates duplication of the Digeorge syndrome critical region (22q11.2). (C) FISH with a Xp22.31 specific region probe;
arrow indicates a deletion of the probe (STS-) in a del(X)(p22.31p22.31) chromosome. (D) FISH with 22q11.2 specific region probe; circles indicate
a duplication of the probe (COMTⅹ3) in an interphase cell.
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(cases 20 and 21). These duplication copy number varia-
tion phenotypes appear to be generally mild and highly
variable; findings ranged from apparently normal to
mental retardation, growth retardation, and autism
(15q11.2 duplication). Therefore, prenatal array CGH
results must be evaluated whether the results show
benign variants or pathogenic variants. Currently, many
useful copy number variation data base websites are
available. For example, the Database of Genomic Var-
iants (http://projects.tcag.ca/variation/), DECIPHER
(http://decipher.sanger.ac.uk/), and Genereviews (http://
www.genetests.org/), which is a more clinically useful
website that lists the associated genetic diseases includ-
ing phenotypes, genotypes, and clinical management of
pathogenic copy number variant diseases. Many known
micro deletion syndromes are expressed by incomplete
penetrance [19], whereas duplications generally produce
milder and, therefore, less identifiable phenotypes than
counterpart deletions [20]. A previous study suggested
an effective general algorithm for clinical testing using
array CGH [21]. Moreover, practical guidelines for array
CGH have been issued by the American College of
Medical Genetics [22,23]. It is important that, with the
exception of purported benign copy number variables
(CNVs), all regions showing abnormal copy number
Figure 2 Array CGH with cytogenetics validation data for case 30 (Table 3). (A), (B) The array CGH results for chromosomes 11 and 22. Arrows
indicates duplication of 11q23 and 22q11.2. (C) G-banding karyotype result of 47,XX, +der(22)t(11;22)(q23;q11). Arrow indicates the marker
chromosome. (D) FISH with 11q23 (green color) and 22q11.2 (yellow color) specific region probes; arrow indicates a +der(22)t(11;22)(q23;q11).
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An increase in the prenatal detection rate of chromo-
some abnormalities would benefit patients seeking
genetic testing prior to delivery [24,25].
In postnatal cases, we identified breakpoints on 17
types of deletion/micro deletion, seven types of duplica-
tion/micro duplication chromosomes and three sSMC
types. Among the 39 positive postnatal cases, five had
an aneuploidy, 23 had a deletion, and 11 had a duplica-
tion (Table 3). Most postnatal cases had clinical indica-
tions with developmental delay or mental retardation.
Therefore, detection rates of chromosomal abnormalities
using array CGH analysis are generally higher than pre-
natal cases. In this study, we analyzed various patients
with clinical indications and/or unknown specific indica-
tions. We observed a 3q24 deletion in a patient (case 5)
with developmental delay, imperforated anus, and cleft
palate. Deletion of the 3q24-q26 region including the
Dandy-Walker malformations (DWM) critical region
(3q24) appears to be associated with a somewhat similar
constellation of findings including craniofacial dys-
morphism (broad and depressed nasal bridge and low
set posteriorly rotated ears), mental retardation, conge-
nital heart defects, and central nervous system malfor-
mations [26]. A previous study reported the critical
region associated with DWM, which encompasses the
ZIC1 and ZIC4 genes, by mapping the 3q24 interstitial
deletions in several individuals with DWM [27]. In case
10, we identified a micro deletion of the 5q35 region
including the NSD1 gene in one Korean patient with
Sotos syndrome (Figure 3). The most common mutation
(50%) was a micro deletion of the 5q35 region including
NSD1 in Japanese patients with Sotos syndrome, while,
in the UK, approximately 70% of patients with Soto syn-
drome have NSD1 point mutations, and only 10% of the
patients have a micro deletion of the 5q35 region [28].
Therefore, further studies will be necessary for a better
understanding of Sotos syndrome in Korean patients.
The most commonly observed deletions were in the
Xp22.31 region. Our patients with Xp22.31 (cases 19
and 27) appeared to be associated with ichthyosis, short
stature, and attention deficit hyperactivity disorder
(ADHD). The Xp22.31 deletion, causing loss of function
of the STS gene, is associated with steroid sulfatase defi-
ciency in males. The STS gene encodes steroid sulfatase,
a membrane-bound microsomal enzyme that is ubiqui-
tously expressed and hydrolyzes several 3-beta-hydro-
xysteroid sulfates, which serve as metabolic precursors
for estrogens, androgens, and cholesterol [29]. A pre-
vious study reported on a patient with a Xp22.3 intersti-
tial deletion that had ichthyosis, dysmorphic features,
and mental retardation with ADHD [30]. We identified
duplication cases at 15q11.2q12 with developmental
delay, autism, and pigmentation disorder (Figure 3). A
previous study reported that this patient had infantile
autism with cytogenetic abnormalities on chromosomal
region 15q11-q13, as reported in patients with autistic
disorder [31]. We identified three marker chromosome
origins (11, 18, and 22 chromosome segments). sSMC
origin analysis is very important for evaluating clinical
phenotypes. The marker chromosome origin and size
appear to result in variable phenotypes [32]. In our
study, we identified a 22q11.2 duplication including the
CES gene and two chromosomes involved in derivative
translocation marker chromosome (22q11&11q23 dupli-
cation) (Figure 2). This sSMC, der(22)t(11;22)(q23;q11),
is related to Emanuel syndrome, which is characterized
by severe mental retardation, microcephaly, failure to
thrive, preauricular tag or sinus, ear anomalies, and cleft
or high-arched palate [33]. These array CGH and other
cytogenetic findings are consistent with the clinical phe-
notypes of Cat eye syndrome and Emmanuel syndrome
with mental retardation. We also identified CNVs (2q13
duplication and 4q32 duplication) in phenotypically nor-
mal individuals from cord bank blood. The clinical sig-
nificance of the 2q13 duplication is still emerging, as
these copy number variations are also found in phenoty-
pically normal and control individuals [34]. Duplication
of 4q32 is a benign copy number variation represented
in a copy number variation database (http://projects.
tcag.ca/variation/).
And also, it is important to address some of the lim-
itations of array CGH before this test is considered for
clinical diagnosis as a firstl i n et e s t .A r r a yC G Hd o e s
not detect polyploidy, balanced translocations, inversions
and low level mosaicims. Marker chromosomes may
also be missed, depending on the size, marker composi-
tion and array coverage of the specific chromosomal
region present on the marker chromosome. And also we
must consider various limitations of array CGH testing
(e.g. point mutations, uniparental disomy and appropri-
ate turnaround times). Therefore, genetics laboratories
must be capable of performing array CGH and concur-
rent conventional cytogenetic analyses (G-banding and
FISH) including molecular genetic analyses (DNA
sequencing etc.) and also clinical geneticists offer appro-
priate genetic counseling including interpretation of
results and limitations of test for patients and family
members.
Conclusions
This study demonstrated that our newly developed array
CGH platform is very useful for clinical implementation
using whole-genome array CGH as first-tier test in 5080
pre and postnatal cases. The application of array CGH
with more extended coverage at disease specific regions
and concurrent appropriate other cytogenetic analyses
such as karyotype and FISH will be useful to
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Page 8 of 10characterize various chromosomal disorders. Further-
more, the newly developed array CGH analysis platform
will lead to a new understanding of genomic disorders
with DNA copy number changes and their relationship
to genotype and phenotype. Additionally, functional stu-
dies based on the identity of the involved genes are
necessary for a further understanding of the mechanism
related to contiguous genes on deletion and duplication
loci in the development and/or progression of various
DNA copy number change disorders.
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Figure 3 Array CGH with FISH validation data for cases 10 (A, C) and 23 (B, D) (Table 3). (A) The array CGH results for chromosome 5.
Arrow indicates deletion of the Sotos syndrome critical region (5q35.3), including the NSD1 gene. (B) The array CGH results for chromosome 15.
Arrow indicates duplication of the PWS/AS syndrome critical region (15q11.2). (C) FISH with a 5q35.3 specific region probe; arrow indicates a
deletion of the probe (NSD1-) in a del(5)(q35.3q35.3) chromosome. Deletion of the NSD1 gene region (red signal) was observed by FISH analysis,
46, XY, ish del(5)(q35.3q35.3)(D5S404+, NSD1-) (D) FISH with 15q11.2 specific region probe; arrows indicate a duplication of the probe (SNRPNⅹ3)
in interphase cells.
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